Vitamin D3 for Life

Live Enlightened

Research libraryVitamin D3 For Life
Study design and methods

Secondary relevance to vitamin D This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

This paper mainly addresses another topic and also reports a vitamin D analysis, result or scientific synthesis.

Why this paper is included

Supporting source evidence:

Implementation status of calcium supplementation for prevention of preeclampsia, by countryCalciumnEMLNational policyTarget populationTrainingTreatment regimen (dose)Data availabilityProduct availabilityBurkina FasoYes*No 6n/aNot includedn/aHMIS: Women with PE/E reported in HMIS; no relevant indicators on product useFAO11: No national survey available, but subnational data from 2010 including women of reproductive age in rural areas, indicating average dietary intake of calcium was low at 497 mg/day.Yes, available in various formulations, such as IDEOS Calcium Carbonate 500 mg (30 tablets per package).EthiopiaYes*Yes 7All pregnant womenIncluded in pre: and in-service training curriculaDaily calcium supplementation during pregnancy: starting from 14 weeks of gestation (1.5 to 2.0 g oral elemental calcium)HMIS: Women with PE/E reported in HMIS; no relevant indicators on product useFAO11: No national survey available; one subnational survey (2013) including mothers and children in rural areas showed calcium intake 363 mg/day; second survey (2013) in pregnant and non-pregnant women in rural areas indicated low calcium intake averaging 268 mg/dayYes, available in various formulations such as CalciD-Denk, 1,000 mg Calcium Carbonate + 22 micro grams vitamin D3 (20 tablets per package).In-country market authorization identified for five products although none are locally manufactured (eRIS, EFDA 2023).KenyaYes*Yes 8Pregnant women with low dietary intake of calcium and/or any pregnant woman with high risk for PE** regardless of calcium dietary intakeIncluded in pre: and in-service training curriculaFor women with low dietary calcium intake recommend starting first trimester, or prior to 16 weeks. (at least 1 g/day orally)HMIS: Women with PE/E reported in HMIS; no relevant indicators on product useFAO11: No national datasetavailable.

Source: Assessment Results. View original paper

Relevance classification does not establish study quality, causation or editorial approval.

Study design Study design awaiting verification.

Study design awaiting verification

The available source does not establish a sufficiently clear study design.

Meta-analysis unclear · Blinding unclear / not reported · Human research reported

How this paper was classified

Automatic source-based classification; awaiting editorial verification. This is not a quality score.

Key informant interview participants were identified through purposive sampling of global and country: based experts.

Source: Methods.

View supporting evidence in the original paper

What the study types mean
Systematic review
Uses explicit methods to identify, assess and summarise research on a defined question.
Scoping review
Maps the extent and characteristics of research on a topic.
Narrative review
Discusses existing research; systematic-review methods have not been established by this classification.
Review / evidence synthesis
Reviews existing research; the exact review methods need further assessment.
Randomised controlled trial
Assigns participants or groups to comparison interventions by chance.
Non-randomised intervention study
Examines an intervention without random allocation.
Cohort study
Examines exposures and outcomes over time within a defined group.
Case-control study
Compares people with an outcome against people without it, examining exposures.
Cross-sectional study
Examines a population at a particular point in time.
Observational study
Observes exposures and outcomes without assigning the exposure; the subtype is not established here.
Case report
Describes an individual case.
Case series
Describes a group of individual cases.
Secondary analysis
Analyses existing study data; this paper is not automatically another independent trial.
Laboratory study
Investigates biological processes in a laboratory setting.
Qualitative study
Examines experiences or meanings using qualitative methods.
Genetic instrumental-variable study
Uses genetic variation as an instrument to investigate relationships; this is not a randomised treatment trial.
Study protocol
Describes planned methods and is not evidence that the planned study has reported results.
Multiple reported designs
More than one design is explicitly reported; examine the supporting methods.
Study design awaiting verification
The available source does not establish a sufficiently clear study design.

Meta-analysis combines numerical results from studies. Blinding describes who was unaware of treatment allocation. Neither is a separate quality grade. Study design, vitamin D relevance and document format are independent filters.

Abstracts

Implementation Status of Low-Dose Aspirin and Calcium Supplementation to Prevent Preeclampsia in Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan

Study design awaiting verification · Maternal and Child Health Journal · 2026

Original publication title

Implementation Status of Low-Dose Aspirin and Calcium Supplementation to Prevent Preeclampsia in Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan

Patricia S. Coffey; Kimberly Mansen; Nesibu Agonafir; Gbenga Ishola; Basilia Coefe Nitiema; Megan E. Parker; Soha Randhawa; Janet Shauri; Katharine D. Shelley

© The Author(s) 2026

Original publication · Publisher record · CC BY 4.0

Source wording retained. Formatting, section navigation and display-title punctuation adapted for this research record.

Authors’ conclusion

Effective implementation of low-dose aspirin and calcium supplementation for preeclampsia prevention will require strengthening antenatal care and provision of services at the primary health care level and enabling the policy environment where needed. Increased coordination around a package of interventions aimed at reducing preeclampsia will also be critical going forward. Practice recommendations on policy, demand, clinical implementation, and monitoring are summarized.

An extract from the source publication. Read it in context.

At a glance

Abstract: What objectives does the paper state?

Hypertensive disorders of pregnancy are a leading cause of maternal death. Global guidance recommends use of low-dose aspirin and calcium supplementation for prevention of preeclampsia. Published literature showcasing the implementation of these guidelines in low: and middle-income countries (LMICs) is sparse.

Source: Purpose

Abstract: Description

The objective of this practice note is to share our findings related to implementation of low-dose aspirin and calcium supplementation for the prevention of preeclampsia in Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan. The experiences from these five countries can illustrate important aspects about the nature and scope of scale of these two evidence-based interventions in LMICs.

Source: Description

Abstract: Assessment

Between May 2023 and March 2024, we conducted policy review and key informant interviews (n = 59) at global and country level. Implementation efforts for the two interventions show variations in the policy environment and clinical practices across countries. Progress toward scale of low-dose aspirin is hampered by variable clinical practices, low provider and community awareness, late antenatal care attendance, and under resourced health systems including weak supply chains. In the case of calcium supplementation, a complicated regimen and conditional global recommendations leaves countries without actionable plans aligning with optimal counseling models for improved adherence.

Source: Assessment

Abstract: Conclusion

Effective implementation of low-dose aspirin and calcium supplementation for preeclampsia prevention will require strengthening antenatal care and provision of services at the primary health care level and enabling the policy environment where needed. Increased coordination around a package of interventions aimed at reducing preeclampsia will also be critical going forward. Practice recommendations on policy, demand, clinical implementation, and monitoring are summarized.

Source: Conclusion
Authors’ abstract

Purpose

Hypertensive disorders of pregnancy are a leading cause of maternal death. Global guidance recommends use of low-dose aspirin and calcium supplementation for prevention of preeclampsia. Published literature showcasing the implementation of these guidelines in low: and middle-income countries (LMICs) is sparse.

Description

The objective of this practice note is to share our findings related to implementation of low-dose aspirin and calcium supplementation for the prevention of preeclampsia in Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan. The experiences from these five countries can illustrate important aspects about the nature and scope of scale of these two evidence-based interventions in LMICs.

Assessment

Between May 2023 and March 2024, we conducted policy review and key informant interviews (n = 59) at global and country level. Implementation efforts for the two interventions show variations in the policy environment and clinical practices across countries. Progress toward scale of low-dose aspirin is hampered by variable clinical practices, low provider and community awareness, late antenatal care attendance, and under resourced health systems including weak supply chains. In the case of calcium supplementation, a complicated regimen and conditional global recommendations leaves countries without actionable plans aligning with optimal counseling models for improved adherence.

Conclusion

Effective implementation of low-dose aspirin and calcium supplementation for preeclampsia prevention will require strengthening antenatal care and provision of services at the primary health care level and enabling the policy environment where needed. Increased coordination around a package of interventions aimed at reducing preeclampsia will also be critical going forward. Practice recommendations on policy, demand, clinical implementation, and monitoring are summarized.

Supplementary Information

The online version contains supplementary material available at 10.1007/s10995-026-04270-3.

Significance

What Is Already Known on This Subject?

What This Study Adds?

Use of low-dose aspirin and calcium supplementation are recommended by the World Health Organization and other normative bodies for prevention of preeclampsia. Documentation of these practices in low: and middle-income countries is sparse.

Application of the Stages of Achieving Effective Coverage and Equity framework to assess implementation status of a specific intervention can illuminate necessary next steps towards achieving equitable coverage. Near-term actions to advance low-dose aspirin and calcium supplementation towards scale are delineated for five countries (Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan).

Supplementary Information

The online version contains supplementary material available at 10.1007/s10995-026-04270-3.

Publication and source details

Original title: Implementation Status of Low-Dose Aspirin and Calcium Supplementation to Prevent Preeclampsia in Burkina Faso, Ethiopia, Kenya, Nigeria and Pakistan

Patricia S. Coffey; Kimberly Mansen; Nesibu Agonafir; Gbenga Ishola; Basilia Coefe Nitiema; Megan E. Parker; Soha Randhawa; Janet Shauri; Katharine D. Shelley

Maternal and Child Health Journal · 2026

© The Author(s) 20262026https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.http://dx.doi.org/10.13039/100000865Bill and Melinda Gates FoundationINV-001347

Repository JATS snapshot; version as supplied

Source retrieved: 2026-11-10T22:22:30.666601+00:00

DOI: 10.1007/s10995-026-04270-3 · PMC13275748